SCHEDULE 13G: Morgan Stanley Discloses Significant Passive Stake in Praxis Precision Medicines, Inc.
Beneficial Ownership Report
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.2% of Praxis Precision Medicines, Inc.'s common stock as of December 31, 2024.
Summary
- Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G indicating their beneficial ownership in Praxis Precision Medicines, Inc.
- As of December 31, 2024, Morgan Stanley beneficially owns an aggregate of 1,157,140 shares of Praxis Precision Medicines, Inc. Common Stock, representing 6.2% of the class.
- Morgan Stanley Capital Services LLC, a subsidiary, beneficially owns 1,045,291 shares, representing 5.6% of the class.
- The filing indicates that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a major financial institution, Morgan Stanley, in a biotechnology company, Praxis Precision Medicines, Inc. Such disclosures are common for large institutional investors who hold stakes above 5% in publicly traded companies, reflecting their portfolio management activities rather than direct strategic involvement in the issuer's operations.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like Morgan Stanley could be perceived positively by other shareholders, potentially indicating institutional confidence in the company, although the filing explicitly states the investment is passive and not for control.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership threshold met). |
| 02/05/2025 | Date the Schedule 13G was signed and filed by Morgan Stanley and Morgan Stanley Capital Services LLC. |
Keywords
Praxis Precision Medicines, Morgan Stanley, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.